In a May 15 statement, the Academy and five peer physician organizations strongly objected(www.groupof6.org) to aggressive political interference in state legislatures across the United States “that inappropriately interfere with the patient-physician relationship, unnecessarily regulate the evidence-based practice of medicine and, in some cases, even criminalize physicians who deliver safe, legal and necessary medical care.”
In a May 8 hearing, AAFP President John Cullen, M.D., told the Senate Finance Committee that MACRA's framework must be improved to address the challenges it now poses for family physicians. The Academy provided lawmakers with written testimony outlining five areas of concern, with Cullen drawing the committee's attention to two of them: creating a culture focused on patient care, and eliminating the complexity in MIPS scoring.
The Academy has gained ground in its ongoing push for drug-pricing transparency. Reflecting recent AAFP advocacy — and over considerable pharmaceutical industry opposition — HHS on May 8 announced revised policy(s3.amazonaws.com) requiring the inclusion of prescription drug prices in TV commercials. The Academy applauds this move to better inform primary care patients.